Primary yolk sac tumour of the prostate mimicking small round blue cell tumour.

We report a rare case of primary yolk sac tumour of the prostate with extensive local and liver metastasis, the latter of which exhibited sheets of small blue cells expressing CD99 and focal sall4 on biopsy. Positivity for CD99 and gata3 in the initial biopsy raised the differential diagnosis of Ewing sarcoma and poorly differentiated carcinoma. The primary tumour demonstrated an admixture of solid and glandular growth patterns and occasional Schiller-Duval bodies. A panel of immunohistochemical stains showing positivity for AE1/3, sall4, cdx2, and focal alpha-fetoprotein, and negativity for oct-4, facilitated the diagnosis. A thorough review of the literature and our current report indicate that a large tumour load, incomplete tumour resection, limited response to preoperative neoadjuvant chemotherapy, and late stage of the disease are predictive factors for a poor clinical outcome. PMID: 31708666 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Related Links:

Conditions:   Adrenocortical Carcinoma;   Pheochromocytoma;   Paraganglioma Intervention:   Drug: EO2401 Sponsor:   Enterome Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Interventions:   Drug: CS1001+ Fluorouracil+Cisplatin;   Drug: Placebo+ Fluorouracil+Cisplatin Sponsor:   CStone Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lymphoma Intervention:   Other: Quality of life Sponsors:   University Hospital, Toulouse;   Force Hémato;   Hospitalidee Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Lung Non-Small Cell Carcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Sta ge IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Intervention:   Drug: Fluorin...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Colon Cancer Intervention:   Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor:   Universidad de León Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Patients With Metastatic Colorectal Cancer Interventions:   Drug: Fluoropyrimidine;   Drug: Bevacizumab Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Melanoma;   Non-small Cell Lung Carcinoma (NSCLC);   Renal Cell Carcinoma (RCC);   Brain Metastases Intervention:   Combination Product: LITT + Pembrolizumab Sponsors:   University of Florida;   Monteris Medical Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: January 2020Source: Journal of Comparative Pathology, Volume 174Author(s): K. Törner, M. Staudacher, U. Tress, C.N. Weber, C. Stadler, J.M. Grassinger, E. Müller, H. Aupperle-LellbachSummaryThe most common pancreatic diseases in cats are pancreatitis and exocrine pancreatic insufficiency (EPI). Non-invasive methods, such as serological quantification of feline pancreatic lipase immunoreactivity (fPLI), are often used in the diagnosis of pancreatitis. Previous studies have compared fPLI concentrations with histopathology, considered to be the gold standard for diagnosis of feline pancreatitis. Ho...
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
CONCLUSIONS Our study using an integrated bioinformatics analysis might provide valuable information for exploring potential new molecular biomarkers and therapeutic targets for OSCC. PMID: 31794546 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSIONS The findings from network meta-analysis showed that fruquintinib was associated with significant superiority for PFS and DCR compared with TAS-102, but fruquintinib was associated with significantly increased risk for SAEs compared with regorafenib and TAS-102. PMID: 31790382 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
More News: Bone Cancers | Cancer & Oncology | Carcinoma | Chemotherapy | Ewing's Sarcoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Sarcomas | Urology & Nephrology | Yolk Sac Tumor